JPRN-jRCT2080222549未知3 期
A double-blind, placebo-control, randomized phase III study to evaluate the efficacy and safety of TAC-202 in patients with perennial allergic rhinitis
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Subjects who have been diagnosed with perennial allergic rhinitis and who have had related symptoms for 2 years or longer.
- •Subjects who showed positive in nasal provocation test with house dust disc.
排除标准
- •Subjects who previously developed anaphylaxis to antihistamine drugs, fexofenadine or ingredients of the investigational drug.
- •Subjects with any of the following complications that may hinder efficacy evaluation
- •- Vasomotor rhinitis, - Eosinophilic rhinitis, - Drug-induced rhinitis,
- •- Viral conjunctivitis, - Otitis media,
- •- Others (acute/chronic rhinitis, hypertrophic rhinitis, sinusitis, nasal polyps, repetitive nasal hemorrhage, treatment-requiring nasal septal deviation, etc.)
研究者
相似试验
进行中（未招募）
不适用
Double-blind, placebo-controlled, randomized phase II-study investigating the efficacy of Bevacizumab for symptom control in patients with malignant ascites due to advanced-stage gastrointestinal cancerspatients with malignant ascites due to advanced-stage gastro-intestinal cancersMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10025538Term: Malignant ascitesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014725-16-DEAIO Studien gGmbH
已完成
不适用
A randomized double-blind placebo-controlled phase 1 study regarding safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of ADRECIZUMAB (HAM 8101) in healthy male subjects.severe bacterial infection.10004018SepsisNL-OMON43493Adrenomed AG24
已完成
不适用
A randomized double-blind placebo-controlled phase I study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of ADRECIZUMAB (HAM8101) in healthy male subjects during experimental endotoxemia.SepsisNL-OMON43006Adrenomed AG24
进行中（未招募）
1 期
Rucaparib maintenance treatment for cervical cancerEUCTR2018-003756-20-SEordic Society of Gynaecological Oncology-Clinical Trial Unit162
进行中（未招募）
1 期
A randomized double-blind placebo-controlled phase 1 study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of AK1967 (Procizumab) in healthy male volunteersCirculatory shockCTIS2023-507035-37-004TEEN4 Pharmaceuticals GmbH24